Prevention of diabetic keratopathy

British Journal of Ophthalmology

Volumn 89, Issue 3, 2005, Pages 254-255

  Kaji, Yuichi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORNEA EPITHELIUM; DIABETES MELLITUS; DIABETIC KERATOPATHY; DIABETIC RETINOPATHY; EDITORIAL; EYE DISEASE; HISTOPATHOLOGY; KERATOPATHY; MORBIDITY; PRIORITY JOURNAL; WOUND HEALING;

ALDEHYDE REDUCTASE; ANIMALS; BASEMENT MEMBRANE; CORNEAL ULCER; DIABETES COMPLICATIONS; DIABETES MELLITUS; EPITHELIUM, CORNEAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS;

EID: 14744274580     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.055541     Document Type: Editorial

References (29)

1. Schultz RO, Van Horn DL, Peters MA, et al. Diabetic keratopathy. Trans Am Ophthalmol Soc 1981;79:180-99.
2. Gekka M, Miyata K, Nagai Y, et al. Corneal epithelial barrier function in diabetic patients. Cornea 2004;23:35-7.
3. Gobbels M, Spitznas M, Oldendoerp J. Impairment of corneal epithelial barrier function in diabetics. Graefes Arch Clin Exp Ophthalmol 1989;227:142-4.
4. Yokoi N, Niiya A, Komuro A, et al. Effects of aldose reductase inhibitor CT-112 on the corneal epithelial barrier of galactose-fed rats. Curr Eye Res 1997;16:595-9.
5. Tsubota K, Yamada M. The effect of aldose reductase inhibitor on the corneal epithelium. Cornea 1993;12:161-2.
6. Meyer LA, Ubels JL, Edelhauser HF. Corneal endothelial morphology in the rat. Effects of aging, diabetes, and topical aldose reductase inhibitor treatment. Invest Ophthalmol Vis Sci 1988;29:940-8.
7. Matsuda M, Awata T, Ohashi Y, et al. The effects of aldose reductase inhibitor on the corneal endothelial morphology in diabetic rats. Curr Eye Res 1987;6:391-7.
8. Ohguro N, Matsuda M, Ohashi Y, et al. Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients. Br J Ophthalmol 1995;79:1074-7.
9. Hosotani H, Ohashi Y, Yamada M, et al. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol 1995;119:288-94.
10. Azar DT, Spurr-Michaud SJ, Tisdale AS, et al. Decreased penetration of anchoring fibrils into the diabetic stroma. A morphometric analysis. Arch Ophthalmol 1989;107:1520-3.
11. Azar DT, Spurr-Michaud SJ, Tisdale AS, et al. Altered epithelial-basement membrane interactions in diabetic corneas. Arch Ophthalmol 1992;110:537-40.
12. Hosotani H, Ohashi Y, Kinoshita S, et al. Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats. Curr Eye Res 1996;15:1005-7.
13. Fujishima H, Shimazaki J, Yogi Y, et al. Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study. Cornea 1996;15:368-75.
14. Schultz RO, Peters MA, Sobocinski K, et al. Diabetic keratopathy as a manifestation of peripheral neuropathy. Am J Ophthalmol 1983;96:368-71.
15. Daubs JG. Diabetes screening with corneal aesthesiometer. Am J Optom Physiol Opt 1975;52:31-5.
16. Akagi Y, Yajima Y, Kador PF, et al. Localization of aldose reductase in the human eye. Diabetes 1984;33:562-6.
17. Kinoshita JH, Fukushi S, Kador P, et al. Aldose reductase in diabetic complications of the eye. Metabolism 1979;28:462-9.
18. Kubo E, Nakamura S, Tsuzuki S, et al. Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats. Graefes Arch Clin Exp Ophthalmol 1999;237:758-62.
19. Awata T, Sogo S, Yamamoto Y. Effects of aldose reductase inhibitor, CT-112, on sugar alcohol accumulation in corneal epithelium of galactose-fed rats. Jpn J Ophthalmol 1986;30:245-50.
20. Awata T, Sogo S, Yamagami Y, et al. Effect of an aldose reductase inhibitor, CT-112, on healing of the corneal epithelium in galactose-fed rats. J Ocul Pharmacol 1988;4:195-201.
21. Datiles MB, Kador PF, Kashima K, et al. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs. Invest Ophthalmol Vis Sci 1990;31:2201-4.
22. Fujishima H, Tsubota K. Improvement of corneal fluorescein staining in past-cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235. Br J Ophthalmol 2002;86:860-3.
23. Saito J, Enoki M, Hara M, et al. Correlation of corneal sensation, but not of basal or reflex tear secretion, with the stage of diabetic retinopathy. Cornea 2003;22:15-18.
24. Nakamura M, Kawahara M, Morishige N, et al. Promotion of corneal epithelial wound healing in diabetic rats by the combination of a substance P-derived peptide (FGLM-NH2) and insulin-like growth factor-1. Diabetologia 2003;46:839-42.
25. Taylor HR, Kimsey RA. Corneal epithelial basement membrane changes in diabetes. Invest Ophthalmol Vis Sci 1981;20:548-53.
26. Kaji Y, Usui T, Oshika T, et al. Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 2000;41:362-8.
27. Kenyan K, Wafai Z, Michels R, et al. Corneal basement membrane abnormality in diabetes mellitus. Invest Ophthalmol Vis Sci 1978;17(Suppl):245.
28. Kaji Y, Amano S, Usui T, et al. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci 2003;44:521-8.
29. Gimbrone MA Jr, Cotran RS, leapman SB, et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974;52:413-27.